WO1999030734A1 - Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer - Google Patents
Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer Download PDFInfo
- Publication number
- WO1999030734A1 WO1999030734A1 PCT/US1998/025725 US9825725W WO9930734A1 WO 1999030734 A1 WO1999030734 A1 WO 1999030734A1 US 9825725 W US9825725 W US 9825725W WO 9930734 A1 WO9930734 A1 WO 9930734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- peptide
- tumor
- vee
- dna
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 61
- 239000013598 vector Substances 0.000 title claims abstract description 49
- 239000000427 antigen Substances 0.000 title claims abstract description 37
- 108091007433 antigens Proteins 0.000 title claims abstract description 37
- 102000036639 antigens Human genes 0.000 title claims abstract description 37
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 title claims description 46
- 230000036039 immunity Effects 0.000 title abstract description 7
- 231100000405 induce cancer Toxicity 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 72
- 238000000034 method Methods 0.000 claims abstract description 51
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 claims abstract description 39
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 claims abstract description 39
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 claims abstract description 39
- 102000004127 Cytokines Human genes 0.000 claims abstract description 32
- 108090000695 Cytokines Proteins 0.000 claims abstract description 32
- 241000700605 Viruses Species 0.000 claims abstract description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 36
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 150000001413 amino acids Chemical group 0.000 claims description 23
- 208000015181 infectious disease Diseases 0.000 claims description 23
- 239000002299 complementary DNA Substances 0.000 claims description 21
- 210000004443 dendritic cell Anatomy 0.000 claims description 19
- 230000002458 infectious effect Effects 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 17
- 125000003729 nucleotide group Chemical group 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 14
- 102000039446 nucleic acids Human genes 0.000 claims description 14
- 150000007523 nucleic acids Chemical class 0.000 claims description 14
- 210000004881 tumor cell Anatomy 0.000 claims description 14
- 230000008569 process Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 10
- 108010002350 Interleukin-2 Proteins 0.000 claims description 10
- 230000001394 metastastic effect Effects 0.000 claims description 10
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 10
- 102000000588 Interleukin-2 Human genes 0.000 claims description 9
- 230000001613 neoplastic effect Effects 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 102000014150 Interferons Human genes 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 5
- 102000013462 Interleukin-12 Human genes 0.000 claims description 5
- 108010065805 Interleukin-12 Proteins 0.000 claims description 5
- 102000003812 Interleukin-15 Human genes 0.000 claims description 5
- 108090000172 Interleukin-15 Proteins 0.000 claims description 5
- 108010002586 Interleukin-7 Proteins 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 239000002054 inoculum Substances 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 229940117681 interleukin-12 Drugs 0.000 claims description 4
- 229940100994 interleukin-7 Drugs 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- CNLKDWSAORJEMW-KWQFWETISA-N Tyr-Gly-Ala Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H](C)C(O)=O CNLKDWSAORJEMW-KWQFWETISA-N 0.000 claims 2
- FUKFQILQFQKHLE-DCAQKATOSA-N Ala-Lys-Met Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O FUKFQILQFQKHLE-DCAQKATOSA-N 0.000 claims 1
- WZZSKAJIHTUUSG-ACZMJKKPSA-N Glu-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O WZZSKAJIHTUUSG-ACZMJKKPSA-N 0.000 claims 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 claims 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 claims 1
- FFKJUTZARGRVTH-KKUMJFAQSA-N His-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O FFKJUTZARGRVTH-KKUMJFAQSA-N 0.000 claims 1
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 claims 1
- MPOHDJKRBLVGCT-CIUDSAMLSA-N Lys-Ala-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N MPOHDJKRBLVGCT-CIUDSAMLSA-N 0.000 claims 1
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 claims 1
- WGDYNRCOQRERLZ-KKUMJFAQSA-N Ser-Lys-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)N WGDYNRCOQRERLZ-KKUMJFAQSA-N 0.000 claims 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 claims 1
- BECPPKYKPSRKCP-ZDLURKLDSA-N Thr-Glu Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BECPPKYKPSRKCP-ZDLURKLDSA-N 0.000 claims 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 claims 1
- DFQZDQPLWBSFEJ-LSJOCFKGSA-N Val-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)O)N DFQZDQPLWBSFEJ-LSJOCFKGSA-N 0.000 claims 1
- 108010093581 aspartyl-proline Proteins 0.000 claims 1
- 229940022399 cancer vaccine Drugs 0.000 claims 1
- 238000009566 cancer vaccine Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 claims 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 claims 1
- 108010056582 methionylglutamic acid Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 22
- 201000011510 cancer Diseases 0.000 abstract description 10
- 230000000890 antigenic effect Effects 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000004748 cultured cell Anatomy 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 42
- 235000001014 amino acid Nutrition 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 20
- 230000028993 immune response Effects 0.000 description 19
- 238000000338 in vitro Methods 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 17
- 238000013459 approach Methods 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 210000000987 immune system Anatomy 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 102000005936 beta-Galactosidase Human genes 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 239000005090 green fluorescent protein Substances 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 210000001165 lymph node Anatomy 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 108090000288 Glycoproteins Proteins 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 3
- 102000000646 Interleukin-3 Human genes 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102100021592 Interleukin-7 Human genes 0.000 description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 3
- 101000726057 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 description 3
- 101710176177 Protein A56 Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 108020005038 Terminator Codon Proteins 0.000 description 3
- 108091036066 Three prime untranslated region Proteins 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- -1 alanine amino acids Chemical class 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 102200044230 rs28937880 Human genes 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000007399 DNA isolation Methods 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102220500686 ELMO domain-containing protein 2_K245N_mutation Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 101800000515 Non-structural protein 3 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 108700010900 influenza virus proteins Proteins 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940076264 interleukin-3 Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- RFKMCNOHBTXSMU-UHFFFAOYSA-N methoxyflurane Chemical compound COC(F)(F)C(Cl)Cl RFKMCNOHBTXSMU-UHFFFAOYSA-N 0.000 description 1
- 229960002455 methoxyflurane Drugs 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 102200155721 rs121918464 Human genes 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/464486—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- VENEZUELAN E Q UINE ENCEPHALITIS VIRUS VECTORS EXPRESSING TUMOR-ASSOCIATED ANTIGENS TO INDUCE CANCER IMMUNITY
- the present invention describes a novel method of inducing immunity to cancer. This invention further discloses the use of Venezuelan Equine
- VEE Encephalitis virus vectors for expression of tumor-associated antigens, tumor-associated antigenic peptides and cytokines and methods for expressing these heterologous products in cultured cells, and in humans or animals.
- Cancer is a leading cause of death.
- Conventional treatment of cancer consists of chemotherapy, radiation therapy, and surgery, or a combination of these approaches.
- Novel and more effective strategies to combat cancer that eliminate the causes of these diseases, or to diminish pain and suffering, thereby prolonging the life of an affected patient are continually sought.
- Tumor cells are known to express antigenic determinants that can be seen by the host's immune system. These determinants, called tumor-associated antigens (TAAs), are often altered or mutated forms of normal host cell proteins or peptides. They can be proteins or peptides that are not normally expressed in the tissue from which the tumor originates (Houghton, J. Exp. Med. 180: 1-4, 1994) and can act like a tag to identify tumor cells.
- TAAs tumor-associated antigens
- One experimental approach to cancer therapy involves inducing the patient's immune system to mount an immune response against the tumor by attacking cells that express the TAAs.
- the role of the immune system is to scan the body for proteins and other molecules that are not normally part of the body, called non-self or foreign antigens. If the immune system encounters a foreign molecule, an immune response is usually initiated.
- the immune response typically is divided into two branches. One branch is the humoral response in which B-cells are induced to produce antibodies against the foreign molecule. These antibodies can bind to the molecules and promote a variety of biological activities.
- the second branch is the cellular branch in which cytotoxic T-cells are induced against the foreign molecule. The cytotoxic T-cells find other cells that express the foreign molecule and kill those cells. Once the immune system is stimulated, long-lived cells are expanded which specifically recognize the foreign antigen upon re-exposure to that antigen.
- One method to induce the immune system to respond to a foreign peptide, protein or organism is to inject that foreign antigen into the body of the host by a process called vaccination.
- the peptide, proteins or organism is delivered to the host in a formulation that is conducive to stimulating the immune system. Should the host come in contact with the foreign antigen in the future, the foreign antigen will be more rapidly and vigorously eliminated by the immune system.
- This approach has been demonstrated to be useful in the infectious disease area where numerous vaccines have protected millions of individuals from viral and bacterial diseases. This experimental approach has met with little success in cancer therapy, however, when TAAs are injected. There are several reasons for the failure of this approach. These include the inability of the immune system to recognize the TAAs.
- TAAs antibodies against the TAAs are induced in the patient, but these seem to be insufficient to alter the course of the disease.
- tumors may secrete factors responsible for dulling the immune response. What often appears to be lacking in the immune response against TAAs is a sufficient cellular response.
- DC progenitor cells originate in the hematopoetic system and reside in the skin and in the areas (interstitial spaces) surrounding cells in different tissues (Schuler and Steinman, J. Exp. Med. 186: 1183-1187, 1997).
- DCs take up proteins and process them intracellularly to smaller peptides which are then transported to the cell surface in combination with a major histocompatibility complex (MHC) protein. It is the combination of appropriate accessory molecules on the cell surface together with the complex of the peptide in association with the MHC protein that serves to "present" antigen to the T-cells.
- MHC major histocompatibility complex
- the interaction of the DC and T-cell is thought to induce the production of cell stimulatory molecules, called cytokines, that stimulate the T-cells to respond to the presented TAA peptide.
- An approach to stimulate the immune response to tumors has been to co- culture or "pulse" DCs with the TAA or related peptides in vitro. After the appropriate amount of time, the DCs are introduced back into the patient.
- TAA or peptides derived from TAAs in DCs in vitro by recombinant
- beta-galactosidase was expressed in mouse DCs after infection of the DCs with an adenovirus vector that expresses beta-galactosidase.
- Introduction of the modified DCs into mice with beta- galactosidase-expressing tumors resulted in prolonged survival of the mice in both a prophylactic and therapeutic approach. Therefore, in these model systems, expression of the model TAA in DCs resulted in enhanced immunity against the tumor.
- TAAs This requires isolation of the TAAs and production in sufficient quantity to be administered to the cells.
- Other methods require infecting the DCs or their precursors with a retrovirus or adenovirus that expresses the TAA in vitro. Since retroviruses only integrate into dividing cells, only a smaller precursor population of DCs are targets for the therapy. This may limit the usefulness of this approach depending on the patient and the extent that these precursors are available.
- One alternative would be to use a system in which the TAA could be delivered directly to the DCs in vivo. Therefore, the DCs would not have to be isolated, expanded, treated in vitro and then re-introduced back into the patient.
- VEE Venezuelan equine encephalitis
- VEE vector Using the same or similar VEE vector one could express a TAA in a cancer patient to stimulate an immune response against the TAA and the corresponding tumor. Since the VEE vector expressing the TAA would target the DC cells in the lymph node, one would anticipate an enhanced immune response against the tumor compared to a vector that did not target DCs. This could be done directly in an outpatient setting without the need to remove the DCs, culture them, expose them to TAA for various periods of time and then reintroduce them back into the patient. Alternatively, one could still culture the DCs in vitro and use the natural affinity of the VEE vector for the DCs to deliver the TAAs. This would be a highly efficient in vitro method of expressing the TAAs and would be expected to stimulate a strong immune response when the modified DCs were administered back to the patient.
- the VEE expressing the TAA could be co-administered or sequentially administered either in vivo or in vitro with different cytokines to help stimulate the DCs and/or the T- cells to respond to the TAA.
- This co-administration could be in the form of another
- VEE expressing the cytokines or injection of purified cytokines.
- An example of a cytokine that stimulates the expansion of DCs is a synthetic molecule called progenipoietin-G (Streeter et al., 38th Annual American Society of Hematology Meeting, San Diego, CA)
- progenipoietin-G a synthetic molecule called progenipoietin-G
- IL-2, IL-7 and IL-12 are known to enhance cytotoxic T lymphocyte responses (Kubo et al., US Patent 5,662,907).
- interferons alpha and beta and interleukin-15 may be valuable in stimulating the antitumor response.
- Synthetic cytokines based on interleukin-3, (WO 94/12638), chimeric fusion proteins between IL-3 and various growth factors (WO 95/21197 and WO 95/21254), and chimeric fusions between TPO and IL-3 (WO 97/12985) are also contemplated.
- PCT/US/95/01000, PCT/US/94/08672, WO 94/21287, US 5,674,486 can also be used.
- the VEE could express just peptides derived from TAAs in both the in vivo and in vitro situations.
- the TAA peptide may be made as a fusion with other peptides known in the art to stimulate the immune response including but not limited to peptides derived from tetanus toxin, Plasmodium falciparum CS protein, or the streptococcus 18 kilodalton protein.
- more that one open reading frame may be expressed from the VEE vector by use of an appropriately placed internal ribosomal entry site between the first open reading frame and the second reading frame.
- the patients may need more that one inoculation of VEE expressing the TAAs or of DCs that were modified by the VEE expressing the TAAs in vitro to see a clinical benefit.
- This boost to the immune response could come in the same form as the original treatment or by any other means.
- One object of the invention is a method of treating a subject who has cancer or who is at high risk of developing a tumor.
- the method comprises administering to the subject a recombinant Venezuelan equine encephalitis (VEE) virus that expresses an effective amount of heterologous substance from a heterologous nucleic acid segment, with the VEE virus containing at least one attenuating mutation.
- the heterologous nucleic acid segment comprises a promoter operable in the subject operatively associated with a nucleic acid encoding a tumor-associated antigen or peptide or cytokine effective in eliciting or enhancing an immune response to the tumor.
- the tumor-associated antigen(s) and related peptides can be taken from, but not limited to, the examples in the literature as reviewed by Houghton (J. Exp. Med. 180: 1-4, 1994), Mumberg et al., (Seminars in Immunology 8: 289-293, 1996) or Boon et al., (Annu. Rev. Immunol. 12: 337-365, 1994) or from any other source including, but not limited to, public and private databases.
- experimental methods of determining tumor-associated antigens are found in the literature, for example Hsu et al., (Nature Med. 2: 52-58, 1996) or Kawakami et al., (Proc. Nat. Acad. Sci.
- VEE vector sequences and manipulations are also found in the scientific and patent literature. These references include but are not limited to Johnston et al., (WO 95/ 32733), Davis et al., (US 5,185,440), Johnston et al., (WO 96/ 37616), Charles et al., (Virol. 228: 153-160, 1997), Caley et al., (J. Virol. 71: 3031-3038, 1997), Davis et al. (J.
- Another aspect of the invention is a DNA compromising a cDNA clone for an infectious Venezuelan equine encephalitis virus RNA transcript which contains at least one attenuating mutation and a heterologous promoter positioned upstream from the cDNA clone and operationally associated therewith.
- the VEE cDNA contains a heterologous promoter operably linked to a cDNA or coding region of a tumor associated antigen, the coding region of a peptide or peptides or the coding region or cDNA of a cytokine.
- a further aspect of the invention is to isolate a patient's dendritic cells and culture them in vitro in an appropriate culture media supportive of growth and maintenance of the DC cell.
- the DC cells are infected in vitro with an infectious recombinant Venezuelan equine encephalitis (VEE) virus with the VEE virus containing at least one attenuating mutation and a heterologous nucleic acid segment.
- the heterologous nucleic acid segment comprises a promoter operable in the subject operatively associated with a nucleic acid encoding a tumor-associated antigen or peptide or cytokine effective in eliciting or enhancing an immune response to the tumor.
- a further aspect of the invention is a method of treating a patient who has cancer or who is at risk of cancer with a viral vector that targets dendritic cells because the viral vector is a pseudotype virus which has the dendritic cell targeting properties of the Venezuelan equine encephalitis virus but may contain components of other viruses.
- the pseudotyped virus contains a heterologous nucleic acid segment which comprises a promoter operable in the subject operatively associated with a nucleic acid encoding a tumor-associated antigen or peptide or cytokine effective in eliciting or enhancing an immune response to the tumor.
- a further aspect of the invention is a DNA that can be packaged into a pseudotyped viral particle that targets to the dendritic cell and contains a heterologous nucleic acid segment which comprises a promoter operable in the subject operatively associated with a nucleic acid encoding a tumor-associated antigen or peptide or cytokine effective in eliciting or enhancing an immune response to the tumor.
- One aspect of the invention is a method of protecting or treating a subject against primary or metastatic neoplastic diseases, comprising: administering a recombinant Venezuelan Equine Encephalitis (VEE) virus vector to said subject in an effective amount, with said VEE virus vector containing at least one attenuating mutation, and with said VEE virus vector containing a heterologous DNA segment, said DNA segment comprising a promoter operably-linked to a DNA encoding a protein or peptide effective for treating said subject from said disease.
- VEE Venezuelan Equine Encephalitis
- the protein or peptide is a tumor-associated antigen. Even more preferably, the tumor-associated antigen is MAGE-1.
- the peptide has the amino acid sequence EADPTGHSY (SEQ ID NO: 4).
- the protein or peptide is fused to another peptide selected from the group consisting of QYIKANSKFIGITE (SEQ ID NO: 6), DIEKKIAKMEKASSVFNWNS (SEQ ID NO: 7), and YGAVDSILGGVATYGAA (SEQ ID NO: 8).
- the heterologous promoter is Venezuelan equine encephalitis 26S subgenomic promoter.
- Another aspect of the invention is a method wherein the administering step is a parental administration.
- the administering step is carried out by topically applying the virus to an airway surface of the subject.
- the administering step is an intranasal administration step.
- the administering step is an inhalation step.
- the protein is an adjunctive agent selected from the group consisting of natural cytokines and synthetic cytokines.
- the cytokines are selected from the group consisting of interleukin-2, interleukin-7, interleukin-12, interleukin-15, interferon, and progenipoietin-G.
- the invention is also directed to a method of modulating tumors in a patient with a VEE virus vector. It is also directed to a method of inhibiting proliferation of tumor cells with a VEE virus vector.
- the tumor is selected from the group consisting of group consisting of lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.
- the invention is also directed to a process of inhibiting elevated numbers of tumor cells comprising administering to a host in need thereof a therapeutically effective amount of a VEE virus vector in unit dosage form. It is also directed to a process of treating primary or metastatic neoplastic diseases comprising administering to a mammalian host suffering therefrom a therapeutically effective amount of a VEE virus vector in unit dosage form.
- the invention is also directed to a method of modulating primary or metastatic neoplastic diseases in a patient comprising the step of administering an effective amount of the protein or peptide to a patient. It is also directed to a method of inhibiting the production of tumor cells in a patient comprising the step of administering an effective amount of the protein or peptide to a patient.
- the tumor cell is characteristic of one selected from the group consisting of lung cancer, breast cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, colon cancer, renal cancer, bladder cancer, melanoma, hepatoma, sarcoma, and lymphoma.
- the invention is also directed to a DNA comprising a cDNA clone coding for an infectious Venezuelan Equine Encephalitis (VEE) virus RNA transcript and a heterologous promoter positioned upstream from said cDNA clone and operatively associated therewith, and further comprising at least one attenuating mutation and containing the nucleotide sequence encoding a TAA, a TAA peptide or a natural or synthetic cytokine linked operably to a promoter.
- VEE Venezuelan Equine Encephalitis
- the invention is also directed to a composition
- a composition comprising a VEE virus vector wherein the protein or peptide is selected from the group consisting of tumor-associated antigens.
- the tumor-associated antigen is MAGE-1.
- the peptide has the amino acid sequence EADPTGHSY
- the protein or peptide is fused to another peptide having the sequence selected from the group consisting of QYIKANSKFIGITE, (SEQ ID NO: 6), DIEKKIAKMEKASSVFNWNS, (SEQ ID NO: 4).
- the composition includes an adjunctive agent selected from the group consisting of natural cytokines and synthetic cytokines.
- the cytokine is selected from the group consisting of are interleukin-2, interleukin-7, interleukin- 12, interleukin-15, interferon or progenipoietin-G.
- the invention also is directed to an infectious VEE virus RNA transcript encoded by a cDNA clone of a recombinant VEE virus vector. It is also directed to infectious VEE virus particles containing such an RNA transcript.
- the invention is also directed to a method of treating a subject against primary or metastatic neoplastic diseases by infecting a subject's dendritic cells with a composition comprising a recombinant VEE virus vector. It is also directed to a pharmaceutical formulation comprising infectious VEE particles in an effective amount in a pharmaceutically acceptable carrier.
- the invention is also directed to an inoculum comprised of an effective amount of nucleic acid encoding a VEE virus vector dissolved or dispersed in an aqueous physiologically-tolerable or pharmaceutically-acceptable diluent. It is also directed to a pharmaceutical composition comprising a therapeutically effective amount of the VEE virus vector in admixture with a pharmaceutically acceptable carrier. It is also directed to a pharmaceutical composition comprising a VEE virus vector, further comprising an adjunctive agent, wherein said adjunctive agent is selected from the group consisting of chemotherapeutic and immunotherapeutic agents.
- the invention is also directed to a process for administering a VEE virus vector to protect or treat a subject against primary or metastatic neoplastic diseases, a process for inhibiting elevated numbers of tumor cells, a process for treating a host with an effective amount of VEE virus vector, and a process for treating a host an effective amount a tumor associated antigen, wherein the administering step in each of these processes is repeated.
- VEE Venezuelan equine encephalitis
- TAA and TAAs mean tumor-associated antigen and tumor-associated antigens, respectively.
- DC and DCs mean dendritic cell and dendritic cells, respectively.
- DNA means deoxyribonucleic acid.
- cDNA means complementary deoxyribonucleic acid.
- RNA means ribose nucleic acid
- oligonucleotide means a single-stranded sequence of nucleotides covalently bound in a 5' to 3' orientation.
- GFP green fluorescent protein
- in vitro means in a test tube or cell culture dish or container.
- in vivo means in a body as opposed to in a test tube or culture dish.
- peptide means a series of amino acids connected to each other by amide bonds between the alpha-amino and carbonyl groups of adjacent amino acids.
- the length of the peptide is not critical and is typically less than about 30 amino acids.
- multimer means one or more reiterations of a sequence of amino acids such as a peptide sequence covalently-linked together by amide bonds.
- vector means any entity that transports a desired component to or in an appropriate host.
- a nucleic acid could be considered a vector when it is used to transport genetic information into a subject.
- a virus particle may be considered a vector to transport proteins or nucleic acids in a host.
- PADRE means any epitope which will bind multiple DR alleles. They are the alleles for Class II MHC (CD4 * T helper cells recognize class II) - stimulate synthesis of IL-2 (growth factor) which then stimulates the CD * T cells (killer T cells or CTLs) among others. The PADRE, therefore, attaches to Class II MHC (CD4 * T helper cells recognize class II) - stimulate synthesis of IL-2 (growth factor) which then stimulates the CD * T cells (killer T cells or CTLs) among others. The PADRE, therefore, attaches to Class II
- the DR epitope is usually 12-25 amino acids.
- DNA is typically purified from bacterial lysates using Promega Wizard Plus Minipreps or Qiagen Plasmid Midi or Maxi kits as per instructions. DNA fragments are isolated from agarose gel after electrophoresis using the Qiagen Qiaex II Gel Extraction Kit (Chatswsorth, CA).
- Baby hamster kidney (BHK-21) cells were used as a host cell for VEE vectors. There are obtained from ATCC (Rockville, MD) and are maintained in Dulbecco's modified Eagle's medium supplemented with 5% fetal bovine serum (FBS). Dendritic cells are maintained in IMDM with 50 ug/ l gentamicin, 73 uM monothioglycerol (Sigma, St. Louis, MO), 20% FBS and various cytokines (see below). Restriction enzymes are available from Gibco/BRL Life Technologies (Rockville, MD), New England Biolabs (Beverly, MA), Promega (Madison, WI) or other suppliers.
- FBS fetal bovine serum
- the restriction enzyme recognition sequences are also found in catalogues of suppliers of the enzymes.
- the standard genetic code can be found in various texts such as Metzler (Biochemistry: The Chemical Reactions of Living Cells, Academic Press, New York, 1977). Three letter and single letter codes for amino acids are also available (Metzler, supra).
- Example 1 Modification of infectious Venezuelan equine encephalitis virus cDNA.
- VEE virus cDNA A molecular clone of VEE virus cDNA is available from ATCC as pV1003 (accession number 68013). This clone has the cDNA downstream from the bacteriophage T7 promoter for in vitro transcription of the viral genome. It was also shown by Davis et al., (US 5,185,440) that there is a 102 base deletion in the nsP3 gene but that RNA transcribed from this cDNA clone is infectious in cell culture and that the deletion mutant is also able to replicate in mice. In order to express a foreign gene, the VEE virus cDNA needs to have an internal promoter to direct expression of that foreign gene. Also useful is a unique restriction enzyme site into which the foreign gene can be easily inserted.
- pV1003 is digested with £coRI and H dIII.
- the approximately 4 kilobase fragment containing the 3' end of the genome can be subcloned into EcoRl and Hindlll digested pAlter-1 (Promega) to yield plasmid pVEEl.
- an oligonucleotide containing the VEE virus 26S promoter is used to alter the VEE virus sequences.
- the oligonucleotide containing the 26S promoter sequences has the sequence: aaacataattga/gaggggcccctataactctctacggctaacctgaatggactacgacatcgattaattaa/ata ca gcagcaa ( ⁇ EQ ID NO: 1 )
- nucleotides on the left are homologous to sequences just downstream (3') of the El gene in the 3' untranslated region of VEE virus.
- sequences between the slashes contain the 26S promoter sequences, the unique Clal site and an ochre translation termination codon in each forward reading frame.
- sequences to the right of the second slash also are homologous to sequences just downstream (3') of the El gene in the 3' untranslated region of VEE virus.
- the resulting plasmid with the desired modifications is identified by CZ ⁇ l digestion and nucleotide sequencing using fluorescent dye terminators using a Perkin Elmer ABI PRISMTM kit (Foster City, CA) and is designated pVEE2.
- pVEE2 and pV1003 are digested with enzymes Tthllll and Notl.
- the approximately 3.9 kilobase pair sequence from pVEE2 is ligated into the larger fragment of pV1003 to yield a new plasmid pVEE3 which now has the second copy of the 26S promoter and a unique CZ ⁇ l site.
- Attenuation mutations in the E2 glycoprotein can be incorporated in the same manner as described above using pVEEl as a target for oligonucleotide- directed mutagenesis. Attenuating mutations have been published by Johnston (WO 95/32733) and Davis (US 5,185,440) and can be accomplished by one skilled in the art using the Altered Sites" Mutagenesis kit as described. Examples of attenuating mutations are Glu76Lys, Thrl20Lys, Glu209Lys or a combination of Glu209Lys and Lys245Asn (using the common three letter code for amino acids and the number indicating the amino acid number in the E2 glycoprotein). The amino acid to the left of the number is the amino acid in the wild type sequence and the amino acid to the right of the number is the amino acid in the attenuated strain at that location.
- TAAs can be introduced into a patient using the VEE virus vector system.
- One such antigen can be isolated from various cancer cells and is designated MAGE-1 (van der Bruggen et al., Science 254: 1643-1647, 1991). The
- MAGE-1 nucleotide sequence is available in Genbank, accession number M77481.
- a cell line or tissue has to be identified that expresses the antigen.
- the human thyroid medullary carcinoma cell line TT is reported to express high levels of MAGE-1 (van der Bruggen et al., Science 254: 1643-1647, 1991).
- This cell line is available from ATCC (ATCC CRL 1803).
- Cells are cultured in Ham's F12 medium with 10% FBS and are plated at about 5 x 10 6 cells per T150 flask. Since the coding region for the MAGE-1 protein is not interrupted by introns, the nucleotide sequence can be isolated from cellular DNA.
- PCR polymerase chain reaction
- the reverse primer has the sequence
- PCR is carried out on a Perkin-Elmer-Cetus DNA Thermocycler at recommended conditions for 30 cycles. 10 microliters of the reaction are analyzed by agarose gel electrophoresis. After staining the gel with ethidium bromide, an approximately 1 kilobase band is present. The amplified DNA is cloned directly into a pGEM-T vector (Promega) as per instructions to yield plasmid pGEM-MAGE-1.
- MAGE-1 DNA sequencing analysis verifies the correct sequence and distinguishes it from other related sequences such as MAGE-2 or MAGE-3 (van der Bruggen et al., Science 254: 1643-1647, 1991). Because the amplified MAGE-1 DNA has CZ ⁇ l sites at each end, it can be removed by CZ ⁇ l digestion from pGEM-MAGE-1 and purified by agarose gel electrophoresis.
- the VEE virus vector, pVEE3 is digested with CZ ⁇ l in the presence of shrimp alkaline phosphatase (US
- truncated regions of MAGE-1 may also be expressed.
- One example is to express a small peptide derived from MAGE-1 that is recognized by cytotoxic T lymphocytes. This small peptide has the amino acid sequence
- oligonucleotide and its complement that encode this peptide are synthesized (Genosys, Woodlands, TX) with the following attributes: a CZ ⁇ l site is synthesized at the immediate 5' end of the sequence followed by a methionine initiation codon, followed by the coding sequence of the following oligonucleotide:
- RNA sequences may be made into a multimers before ligating into the vector.
- the peptide coding region (without the CZ ⁇ l sites and the termination codon but with the initiator methionine codon at the 5' end) can be synthesized with an overlapping Hindlll site at the 5' and the 3' ends. These are ligated together after annealing using T4 DNA ligase to form multimers whose size can be evaluated by polyacrylamide gel electrophoresis. Phosphorylated adapter molecules which include a CZ ⁇ l site 5' of a overhanging i ⁇ dIII site are ligated to the ends of the multimers. The multimers with the CZ ⁇ l adaptors on the ends are digested with CZ ⁇ l and ligated into pVEE3 as above.
- MAGE-1 peptide can be synthesized by adding amino acid linker regions to the target peptide sequence. These linkers can be in the form of a string of alanine amino acids.
- gaagcagaccccaccggccactcctat SEQ ID NO : 5
- its complementary sequence would be modified by incorporating the codons for alanine during the synthesis of the oligonucleotides in the desired number at either the 5' or 3' ends.
- a codon for the initiator methionine amino acid needs to be positioned appropriately at the 5' end of any designed oligonucleotide for proper translation.
- Multimers of SEQ ID NO: 5 with alanine linkers can be constructed using the same tactics described above.
- any other amino acid may be used to form a linker, preferably glycine or serine.
- alternating or any other sequence arrangement of alanine and glycine and serine may be used.
- the target peptide may also be expressed as a fusion with other peptides that stimulate the immune system.
- Examples of such peptides are sequences from tetanus toxin amino acid sequences 830-843
- peptides may be fused at the amino terminal or carboxyl terminal end of the MAGE-1 peptide epitope by conventional molecular biology techniques as described above.
- various sized linkers such as alanine, serine and/or glycine amino acids can be used to space the peptide sequences to a desired distance.
- Example 4 Isolation and cloning of a cytokine sequence into a VEE virus vector.
- cytokine is interleukin-2 (IL-2) (Taniguchi et al., Nature 302: 305-310, 1983).
- IL-2 interleukin-2
- a plasmid that contains the human IL-2 cDNA is available from ATCC (pLW81, ATCC number 61390).
- the nucleotide sequence of the human IL-2 coding region is available in Genbank (accession number A06759). Plasmid pLW81 can be used as a template using PCR to generate the IL-2 coding region with CZ ⁇ l ends.
- the forward primer has the sequence:
- the reverse primer has the sequence:
- nucleotides to the left of the slash form a CZ ⁇ l restriction site and the nucleotides to the right of the slash are homologous to the 3' untranslated region of the gene.
- the PCR product is ligated into pGEM-T as described above to form pGEM-IL-2.
- the IL-2 gene is removed from pGEM-IL-2 by CZ ⁇ l digestion and ligated into pVEE3 as described above.
- Example 5 Isolation and culturing of human dendritic cells.
- Human DCs are accessible from either cord blood (Romani et al., J. Exp. Med. 180: 83-93, 1994) or from bone marrow (Szabolcs et al., J. Immunology 154: 5851-5861, 1995). Briefly, bone marrow cells are centrifuged in standard Ficoll- Hypaque gradients and the mononuclear cells are isolated from the interface.
- Plasmid pVEE3 and derivatives are digested with Not! to linearize the plasmid and run-off transcripts are generated by T7 RNA polymerase as described (Davis et al., US Patent 5,185,440). Transcripts are transfected into BHK-21 cells as described (Polo et al., Journal of Virology 62: 2124-2133, 1988) using DEAE- Dextran (Sigma, St. Louis, MO) although electroporation and transfection by liposome reagents are also acceptable. After about 24 to 60 hours, when cytopathic effects have peaked, the supernatant is harvested. The quantity of infection virus is determined by standard plaque assays or infectivity assays in BHK-21 cells
- Virus is expanded on BHK-21 cells and further purified by sucrose gradient techniques using endotoxin free sucrose. Briefly, cells are infected using a multiplicity of infection (MOD of 1 infectious unit of virus per cell. The supernatant is aspirated from the cells and overlayed with a minimal volume of virus such that the cells are just submerged. After 30 to 60 minutes at 37°C with occasional rocking to prevent drying, an appropriate volume of medium is added to the cells for normal culturing. Virus is harvested when cytopathic effects have peaked.
- MOD multiplicity of infection
- dendritic cells can be infected at a lower MOI between 0.001 and 01. After absorption of the virus, the cells are washed three times in phosphate-buffered saline with 5% autologous serum and administered back to the host by intravenous infusion over an hour period.
- Example 7 Inoculation of VEE virus vectors into a host.
- MA are put under light Metofane anesthesia (Pitman-Moore). They are inoculated in the rear footpad with an appropriate amount of virus inoculum, preferably about 10 4 infectious units, suspended in a 10 microliter volume of phosphate-buffered saline containing 5% donor calf serum(Caley et al, Journal of Virology, 71: 3031- 3038, 1997). Reinoculation or "boosting" with a given virus is given at timed intervals such as 3 weeks using approximately 10 5 infectious units per footpad. For nasal inoculation, the mice are anesthetized and a pipetman is use to deliver 5-10 ul of inoculum to the nares.
- virus inoculum preferably about 10 4 infectious units, suspended in a 10 microliter volume of phosphate-buffered saline containing 5% donor calf serum(Caley et al, Journal of Virology, 71: 3031- 3038, 1997). Reinoculation or
- the virus is diluted as above and 10 2 to 10 7 infectious units are delivered with a 27-guage needle.
- Serum samples can be obtained from tail vein bleeds at various times post- inoculation or post-boosting to determine antibody titers.
- VEE virus vaccine vector Expression of HIV-1 and Influenza genes in cell culture and protection against influenza challenge in mice immunized with a vector expression HA. Vaccines 95. Cold Spring Harbor, Cold Spring Harbor Laboratory Press: 387-391, (1995).
- Venezuelan equine encephalitis virus RNA from a cDNA clone analysis of a viable deletion mutant. Virology 171(1): 189-204, (1989).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002309765A CA2309765A1 (fr) | 1997-12-18 | 1998-12-14 | Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer |
EP98961904A EP1039926A1 (fr) | 1997-12-18 | 1998-12-14 | Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer |
AU17106/99A AU1710699A (en) | 1997-12-18 | 1998-12-14 | Venezuelan equine encephalitis virus vectors expressing tumor-associated antigens to induce cancer immunity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6808097P | 1997-12-18 | 1997-12-18 | |
US60/068,080 | 1997-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999030734A1 true WO1999030734A1 (fr) | 1999-06-24 |
Family
ID=22080300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/025725 WO1999030734A1 (fr) | 1997-12-18 | 1998-12-14 | Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1039926A1 (fr) |
AU (1) | AU1710699A (fr) |
CA (1) | CA2309765A1 (fr) |
WO (1) | WO1999030734A1 (fr) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051263A3 (fr) * | 1998-04-08 | 2000-02-03 | Univ North Carolina | Methodes et cellules modifiees pour le traitement du cancer |
WO2000015264A1 (fr) * | 1998-09-15 | 2000-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Injection in situ de cellules presentant un antigene a expression de la cytokine genetiquement amelioree |
WO2001021199A1 (fr) * | 1999-09-23 | 2001-03-29 | Thomas Brocker | Vaccin a adn cible sur les cellules dendritiques a efficacite elevee |
US6342372B1 (en) | 1993-09-15 | 2002-01-29 | Chiron Corporation | Eukaryotic layered vector initiation systems for production of recombinant proteins |
US6767699B2 (en) | 2000-05-31 | 2004-07-27 | Chiron Corporation | Method for the quantitation of alphavirus replicon particles |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
US7811812B2 (en) | 1996-04-05 | 2010-10-12 | Novartis Vaccines & Diagnostics, Inc. | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
US8486420B2 (en) | 2005-02-15 | 2013-07-16 | The University Of North Carolina At Chapel Hill | Live virus vaccines |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004542A1 (fr) * | 1993-08-06 | 1995-02-16 | Cytel Corporation | Clonage et description des caracteristiques du gene mage-1 complet |
WO1995020974A1 (fr) * | 1994-02-01 | 1995-08-10 | Ludwig Institute For Cancer Research | Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1 |
WO1995032733A1 (fr) * | 1994-05-27 | 1995-12-07 | The University Of North Carolina At Chapel Hill | Procede d'induction de reaction immunitaire au moyen d'un virus vivant de l'encephalite equine de venezuela exprimant un immunogene heterologue |
WO1997024447A1 (fr) * | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation a mediation par cellules dendritiques modifiees par des genes |
WO1998008947A1 (fr) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Amelioration de l'immunisation a l'adn obtenu a l'aide de cytokines |
-
1998
- 1998-12-14 WO PCT/US1998/025725 patent/WO1999030734A1/fr not_active Application Discontinuation
- 1998-12-14 EP EP98961904A patent/EP1039926A1/fr not_active Withdrawn
- 1998-12-14 AU AU17106/99A patent/AU1710699A/en not_active Abandoned
- 1998-12-14 CA CA002309765A patent/CA2309765A1/fr not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004542A1 (fr) * | 1993-08-06 | 1995-02-16 | Cytel Corporation | Clonage et description des caracteristiques du gene mage-1 complet |
WO1995020974A1 (fr) * | 1994-02-01 | 1995-08-10 | Ludwig Institute For Cancer Research | Anticorps monoclonaux qui se fixent a un precurseur de l'antigene de rejet de tumeurs et qui est du type mage-1, mage-1 produit par recombinaison ou un peptide immunogene derive de mage-1 |
WO1995032733A1 (fr) * | 1994-05-27 | 1995-12-07 | The University Of North Carolina At Chapel Hill | Procede d'induction de reaction immunitaire au moyen d'un virus vivant de l'encephalite equine de venezuela exprimant un immunogene heterologue |
WO1998008947A1 (fr) * | 1995-12-19 | 1998-03-05 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Amelioration de l'immunisation a l'adn obtenu a l'aide de cytokines |
WO1997024447A1 (fr) * | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation a mediation par cellules dendritiques modifiees par des genes |
Non-Patent Citations (4)
Title |
---|
BROSSART P ET AL.: "Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL", J.IMMUNOL., vol. 158, 1997, pages 3270 - 3276, XP002102050 * |
RUSSO, V. ET AL: "Transfer of tumor-associated antigen genes into dendritic cells for activ immunotherapy of neoplastic diseases.", BLOOD, (NOV. 15, 1997) VOL. 90, NO. 10 SUPPL. 1 PART 1, PP. 405A. MEETING INFO.: 39TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY SAN DIEGO, CALIFORNIA, USA DECEMBER 5-9, 1997 THE AMERICAN SOCIETY OF HEMATOLOGY. ISSN: 0006-4971., XP002101280 * |
TUTING T ET AL: "Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha.", JOURNAL OF IMMUNOLOGY, (1998 FEB 1) 160 (3) 1139-47. JOURNAL CODE: IFB. ISSN: 0022-1767., United States, XP002102051 * |
TUTING T ET AL: "Gene-based strategies for the immunotherapy of cancer.", JOURNAL OF MOLECULAR MEDICINE, (1997 JUL) 75 (7) 478-91. REF: 142 JOURNAL CODE: B8C. ISSN: 0946-2716., GERMANY: Germany, Federal Republic of, XP002101281 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376236B1 (en) | 1993-09-15 | 2002-04-23 | Chiron Corporation | Recombinant alphavirus particles |
US7977091B2 (en) | 1993-09-15 | 2011-07-12 | Novartis Vaccines & Diagnostics, Inc. | Eukaryotic layered vector initiation systems |
US7572628B2 (en) | 1993-09-15 | 2009-08-11 | Novartis Vaccines And Diagnostics, Inc. | Eukaryotic layered vector initiation systems |
US6342372B1 (en) | 1993-09-15 | 2002-01-29 | Chiron Corporation | Eukaryotic layered vector initiation systems for production of recombinant proteins |
US7811812B2 (en) | 1996-04-05 | 2010-10-12 | Novartis Vaccines & Diagnostics, Inc. | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
US6844188B1 (en) | 1998-04-08 | 2005-01-18 | University Of North Carolina At Chapel Hill | Methods and modified cells for the treatment of cancer |
WO1999051263A3 (fr) * | 1998-04-08 | 2000-02-03 | Univ North Carolina | Methodes et cellules modifiees pour le traitement du cancer |
US6482405B1 (en) | 1998-09-15 | 2002-11-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | In situ injection of antigen-presenting cells with genetically enhanced cytokine expression |
WO2000015264A1 (fr) * | 1998-09-15 | 2000-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Injection in situ de cellules presentant un antigene a expression de la cytokine genetiquement amelioree |
US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
WO2001021199A1 (fr) * | 1999-09-23 | 2001-03-29 | Thomas Brocker | Vaccin a adn cible sur les cellules dendritiques a efficacite elevee |
US6767699B2 (en) | 2000-05-31 | 2004-07-27 | Chiron Corporation | Method for the quantitation of alphavirus replicon particles |
US7862829B2 (en) | 2004-07-09 | 2011-01-04 | University Of North Carolina At Chapel Hill | Viral adjuvants |
US8821897B2 (en) | 2004-07-09 | 2014-09-02 | The University Of North Carolina At Chapel Hill | Viral adjuvants |
US8486420B2 (en) | 2005-02-15 | 2013-07-16 | The University Of North Carolina At Chapel Hill | Live virus vaccines |
Also Published As
Publication number | Publication date |
---|---|
AU1710699A (en) | 1999-07-05 |
EP1039926A1 (fr) | 2000-10-04 |
CA2309765A1 (fr) | 1999-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rosenberg et al. | Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen | |
Porgador et al. | Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. | |
AU724546B2 (en) | Induction of CTLs specific for natural antigens by cross-priming immunization | |
Ribas | Genetically modified dendritic cells for cancer immunotherapy | |
CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
Schneeberger et al. | CpG motifs are efficient adjuvants for DNA cancer vaccines | |
WO1998000163A9 (fr) | Induction des lymphocytes t cytotoxiques specifiques contre des antigenes naturels par immunisation par amorçage croise | |
US10316332B2 (en) | Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product | |
ES2286104T3 (es) | Vacuna contra tumores especificos del riñon dirigida contra el antigeno g-250 del tumor de riñon. | |
Kaufman et al. | Strategies for cancer therapy using carcinoembryonic antigen vaccines | |
Okada et al. | Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice | |
WO1999030734A1 (fr) | Vecteurs viraux de l'encephalite equine venezuelienne exprimant des antigenes associes aux tumeurs, suscitant une immunite contre le cancer | |
Huang et al. | Intradermal administration of DNA vaccines combining a strategy to bypass antigen processing with a strategy to prolong dendritic cell survival enhances DNA vaccine potency | |
Leitner et al. | Nucleic acid for the treatment of cancer: genetic vaccines and DNA adjuvants | |
Schlom et al. | The diversity of T‐cell co‐stimulation in the induction of antitumor immunity | |
Moret-Tatay et al. | Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors | |
JP2022539157A (ja) | 新規な癌抗原及び方法 | |
Nair et al. | RNA-transfected dendritic cells | |
Nawrath et al. | Synergistic effect of a combined DNA and peptide vaccine against gp100 in a malignant melanoma mouse model | |
Behboudi et al. | Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction | |
JP4459060B2 (ja) | ポリヌクレオチドからなるワクチン | |
Tüting et al. | The immunology of DNA vaccines | |
Li et al. | Murine tyrosinase expressed by a T7 vector in bone marrow–derived dendritic progenitors effectively prevents and eradicates melanoma tumors in mice | |
CA2460809A1 (fr) | Vaccins polynucleotides | |
Himoudi et al. | Development of anti-PAX3 immune responses; a target for cancer immunotherapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2309765 Country of ref document: CA Ref country code: CA Ref document number: 2309765 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 538713 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998961904 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998961904 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998961904 Country of ref document: EP |